In addition, aberrant TAL-1 activation, which is detected in up to 60% of T cell acute lymphoblastic leukemias (T-ALLs) [67], was shown to transcriptionally target TRIB2 [68], allowing TRIB2 to positively reinforce an oncogenic transcriptional program involving GATA3, RUNX1, MYB, and E2A, potentially balancing the oncogenic and tumor-suppressive biological activities of these factors [69]. Here, TRIB2 is linked to neoplasm.